Anzeige
Mehr »
Login
Dienstag, 28.09.2021 Börsentäglich über 12.000 News von 673 internationalen Medien
Kurschance? Countdown mit Ansage: Last Call!?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 565131 ISIN: DK0010272202 Ticker-Symbol: GE9 
Tradegate
28.09.21
09:25 Uhr
365,00 Euro
-1,70
-0,46 %
1-Jahres-Chart
GENMAB A/S Chart 1 Jahr
5-Tage-Chart
GENMAB A/S 5-Tage-Chart
RealtimeGeldBriefZeit
362,20363,0010:26
362,60362,8010:25

Aktuelle News zur GENMAB Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoGenmab Has Blockbuster in Tivdak, Nordea Says, Lifting Price Target240(PLX AI) - Genmab may see Tivdak peak sales of $1.11 billion, Nordea analysts forecast, raising their price target on the stock.• Price target raised to DKK 3,188 from DKK 3,058, with recommendation...
► Artikel lesen
GENMAB Aktie jetzt für 0€ handeln
DoNasdaq Copenhagen A/S: Genmab A/S - admittance to trading and official listing of new shares due to employee warrant exercise283The share capital of Genmab A/S has been increased. The admittance to trading and official listing will take effect as per 24 September 2021 in the ISIN below. ISIN: DK0010272202 ...
► Artikel lesen
MiFDA approves Seagen/Genmab's antibody-drug conjugate Tivdak for women with advanced cervical cancer10
21.09.Genmab A/S: Capital Increase in Genmab as a Result of Employee Warrant Exercise4
21.09.Seagen, Genmab antibody drug conjugate gets FDA approval in cervical cancer5
21.09.Why Genmab's Stock Is Trading Higher Today2
21.09.Seagen, Genmab gun for Merck's Keytruda in cervical cancer with accelerated FDA nod for ADC therapy Tivdak4
21.09.FDA Gives Accelerated Approval to Seagen - Genmab's ADC In Cervical Cancer6
21.09.Genmab Rises More Than 2% After FDA Approves Cervical Cancer Treatment as Expected137(PLX AI) - Genmab shares rose more than 2% after the FDA issued accelerated approval for TIVDAK, a treatment for cervical cancer.• The approval was widely expected in the market• It's a relatively small...
► Artikel lesen
21.09.FDA hands accelerated nod to Seagen, Genmab's solo ADC in cervical cancer, but combo studies look even more promising2
21.09.Genmab, Seagen, Lennar, SmileDirect See After-Hours Moves7
20.09.Seagen/Genmab receive FDA accelerated approval for Tivdak for cervical cancer5
20.09.Genmab Says FDA Granted Accelerated Approval for TIVDAK in Cervical Cancer235(PLX AI) - Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer.• TIVDAK is a First-in-Class Antibody-Drug...
► Artikel lesen
20.09.Seagen Inc.: Seagen and Genmab Announce FDA Accelerated Approval for TIVDAK (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer303- TIVDAK is a First-in-Class Antibody-Drug Conjugate Directed to Tissue Factor, a Protein Expressed on Cervical Cancer Cells - - New Monotherapy Approved for Use in a Cancer with Limited Treatment...
► Artikel lesen
20.09.Genmab A/S: Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer301TIVDAK is a First-in-Class Antibody-Drug Conjugate Directed to Tissue Factor, a Protein Expressed on Cervical Cancer Cells New Monotherapy Approved for Use in a Cancer with Limited Treatment...
► Artikel lesen
20.09.Seagen, Genmab Present Tisotumab Vedotin Combo Data In Cervical Cancer4
20.09.Seagen/Genmab presents interim results from tisotumab vedotin combo therapy in cervical cancer4
19.09.Seagen Inc.: Seagen and Genmab Present Interim Results From the innovaTV 205 Study for Tisotumab Vedotin Combination Therapy Treatment of Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2021486- Tisotumab Vedotin in Combination with Carboplatin Showed Encouraging, Durable Anti-Tumor Activity as First-Line Treatment - - Tisotumab Vedotin in Combination with Pembrolizumab Showed Encouraging...
► Artikel lesen
19.09.Genmab A/S: Genmab and Seagen Present Interim Results From the innovaTV 205 Study for Tisotumab Vedotin Combination Therapy Treatment of Recurrent or ...3
16.09.ANALYSE-FLASH: Jefferies senkt Genmab auf 'Hold' - Ziel hoch auf 3035 Kronen120NEW YORK (dpa-AFX Broker) - Die Investmentbank Jefferies hat Genmab von "Buy" auf "Hold" abgestuft, das Kursziel aber von 2800 auf 3035 dänische Kronen angehoben. Das Chance/Risiko-Verhältnis könnte...
► Artikel lesen
Seite:  Weiter >>
114 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,3